Mr. Talamo brings over 25 years of experience
leading financial strategies to support both publicly traded and
privately held development and commercial stage biopharmaceutical
companies
SHELTON,
Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity
Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage
biotechnology company focused on the discovery and development of
proprietary, novel immune-based intratumoral cancer therapies
designed to kill tumors and increase immune system recognition of
cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO).
Mr. Talamo will be working at Intensity headquarters as a full
time employee. An accomplished executive with more than 25 years of
leadership experience in the biotechnology space, Mr. Talamo most
recently served as Senior Vice President and Chief Financial
Officer of HiberCell. Mr. John
Wesolowski will remain as the Company's Principal Accounting
Officer and Controller.
"I am delighted to welcome Joe to Intensity, his
wealth of experience as a biotechnology executive and track record
of success in leading financial operations will prove invaluable as
we transition to a late-stage clinical company," said Lewis H. Bender, President and Chief Executive
Officer of Intensity. "I look forward to leveraging his versatile
experience as we pursue our goal of treating solid tumors with our
lead asset INT230-6."
As CFO, Mr. Talamo will develop and implement
Intensity's financial strategies and lead financial reporting,
finance corporate development, strategy and investor relations
efforts while supporting the Company's overall business goals. Most
recently, Mr. Talamo served as the CFO of HiberCell, building the
financial and accounting function, and overseeing the evaluation of
financing and strategic initiatives. Prior to HiberCell, Mr. Talamo
spent ten years at Caladrius Biosciences, a clinical-stage biotech
company dedicated to the development of cellular therapies, most
recently serving as CFO. Before his tenure at Caladrius
Biosciences, Mr. Talamo served as Vice President and Corporate
Controller for OSI Pharmaceuticals. Mr. Talamo holds an MBA in
Finance and a BBA in Accounting from Hofstra
University. He also is a CPA registered in New York.
"I am thrilled to join Intensity at this
pivotal time in the Company's evolution as its lead candidate
INT230-6 is anticipated to enter a Phase 3 clinical trial," said
Mr. Talamo. "Intensity's novel intratumoral delivery technology is
at the forefront of innovation. I look forward to working closely
with the team to advance Intensity's financial strategy and further
its mission to improve the lives of patients who are impacted by
the debilitating effects of cancer."
About INT230-6
INT230-6, Intensity's
lead proprietary investigational product candidate, is designed for
direct intratumoral injection. INT230-6 was discovered using
Intensity's proprietary DfuseRx℠ technology platform. The drug is
composed of two proven, potent anti-cancer agents, cisplatin and
vinblastine, and a penetration enhancer molecule (SHAO) that helps
disperse potent cytotoxic drugs throughout tumors for diffusion
into cancer cells. These agents remain in the tumor resulting in a
favorable safety profile. In addition to local disease control,
direct killing of the tumor by INT230-6 releases a bolus of
neoantigens specific to the patient's malignancy, leading to
engagement of the immune system and systemic anti-tumor effects.
Importantly, these effects are mediated without immunosuppression
that so often occurs with systemic chemotherapy.
About Intensity Therapeutics
Intensity
Therapeutics is a late-stage biotechnology company that applies
novel engineered chemistry to turn "cold" tumors "hot" by enabling
its aqueous cytotoxic-containing drug product, INT230-6, to mix and
saturate the dense, high-fat pressurized environment of the tumor.
As a result of the saturation, Intensity's clinical trials have
demonstrated the ability of INT230-6 to kill tumors and elicit an
adaptive immune response within days of injection, representing a
truly novel approach to cancer cell death that holds the potential
to shift the treatment paradigm and turn many deadly cancers into
chronic diseases. For more information about the Company, including
publications, papers and posters about its novel approach to cancer
therapeutics, visit www.intensitytherapeutics.com. INT230-6
has completed enrollment of over 200 patients in two phase 2 and
phase 1 dose escalation clinical trials (NCT03058289 and
NCT04781725) with various advanced solid tumors; IT-01 in
metastatic disease, and IT-02 the INVINCIBLE study,
in presurgical breast cancer. The Company partnered with Merck
Sharpe & Dohme (Merck) to evaluate the combination of INT230-6,
Intensity's lead product candidate, and KEYTRUDA® (pembrolizumab),
Merck's anti-PD-1 (programmed death receptor-1) therapy, in
patients with advanced pancreatic, colon, squamous cell and bile
duct malignancies. The Company also partnered with Bristol-Myers
Squibb to evaluate the combination of INT230-6 with Bristol-Myers
Squibb's anti-CTLA-4 antibody, ipilimumab, in patients with
advanced liver, breast and sarcoma cancers. Intensity managed the
individual combination arms separately with each respective partner
via a joint development committee. The Company also executed
agreements with the Ottawa Hospital Research Institute (OHRI) and
the Ontario Institute of Cancer Research (OICR) to study INT230-6
in the INVINCIBLE study, a randomized controlled neoadjuvant phase
2 study in women with early-stage breast cancer.
Forward-Looking Statements
Certain
statements in this press release may constitute "forward-looking
statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. These
statements include, but are not limited to, statements relating to
the expected future plans, development activities, projected
milestones, business activities or results. We have based these
forward-looking statements on our current expectations and
projections about future events, nevertheless, actual results or
events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, include: the risk that the anticipated
milestones may be delayed or not occur or be changed, as well as
other risks described in the section entitled "Risk Factors" in the
Company's SEC filings, which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations and beliefs. The Company does not plan to
update any such forward-looking statements and expressly disclaims
any duty to update the information contained in this press release
except as required by law.
Investor Relations Contact:
Argot Partners
Jonathan Nugent
Intensity@argotpartners.com
Media Contact:
Argot Partners
David Rosen
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-appoints-joseph-talamo-cpa-as-chief-financial-officer-302011949.html
SOURCE Intensity Therapeutics Inc.